What is the global market size of Recombinant DNA Technology Market?

Global Recombinant DNA Technology Market size was valued at USD 141.96 billion in 2021 and is poised to grow from USD 152.79 billion in 2022 to USD 274.52 billion by 2030, growing at a CAGR of 7.6% in the forecast period (2023-2030).

Recombinant DNA Technology Market Size, Share, Growth Analysis, By Product(Medical (Therapeutic Agent, Human Protein, Vaccines), Non-Medical (Biotech Crops), By Component(Expression System (Mammalian, Bacteria, Yeast, Baculovirus/Insect)), By Application(Health and disease (Human, Animal), Food and Agriculture, Environment), By End User(Pharmaceutical and biotechnology companies, Research institutes, Others), By Region - Industry Forecast 2024-2031

Q: Which region accounted for the largest share in Global Recombinant DNA Technology Market?

North America dominated the global market. The largest portion of the North American continent can be ascribed to the country's high concentration of biopharmaceutical manufacturing companies. Development aid has also been aided by the existence of powerful regulatory bodies that can keep an eye on the numerous ethical and scientific issues raised by the use of technology.

Report ID: SQMIG35H2067 | Region: Global | Published Date: February, 2024
Pages: 242 | Tables: 124 | Figures: 77

Recombinant DNA Technology Market News

In March 2022, For the purpose of preventing infection by any known subtype of the hepatitis B virus (HBV) in people 18 years of age and older, VBI Vaccines Inc. recombinant hepatitis B vaccine PreHevbrio was first given to Americans.

In February 2022, The European Medicines Agency's Committee for Medicinal Products for Human Use gave the 3-antigen hepatitis B (HBV) vaccine, marketed under the trade name PreHevbri, its seal of approval for adults seeking active immunization against infection brought on by any of the known subtypes of the hepatitis B virus.

Recombinant DNA Technology Market Report Snapshots

License Type Top market research company in USA

File Type

$5,300

BUY NOW GET FREE SAMPLE

Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Recombinant DNA Technology Market size was valued at USD 141.96 billion in 2019 and is poised to grow from USD 152.79 billion in 2023 to USD 274.52 billion by 2031, growing at a CAGR of 7.6% in the forecast period (2024-2031).

These participants are working together in alliances to provide their services in a variety of life science fields. Also, as a realistic tactic to maintain competitiveness in the market, companies are growing constantly their manufacturing facilities. 'Thermo Fisher Scientific Inc.', 'Merck KGaA', 'GenScript Biotech Corporation', 'Horizon Discovery Group plc', 'Lonza Group AG', 'Novartis AG', 'Integrated DNA Technologies, Inc.', 'Genentech, Inc.', 'Amgen Inc.', 'Biogen Inc.', 'Illumina, Inc.', 'Agilent Technologies, Inc.', 'Roche Holding AG', 'Qiagen N.V.', 'Eurofins Scientific SE', 'Takara Bio Inc.', 'Celgene Corporation', 'Bio-Rad Laboratories, Inc.', 'Gensight Biologics S.A.', 'Promega Corporation'

During the forecast period, market expansion is expected to be driven by increasing strategic collaborations between leading market players to advance recombinant DNA technology. To create novel therapeutics based on recombinant DNA technologies, key market players strategically work with large biopharmaceutical companies and research institutions. Such market-wide strategic alliances are anticipated to spur market expansion soon.

A large amount of public acceptance is now being acquired for the development of genetically modified crops in agriculture to increase yield and resistance to herbicides or pesticides. The genetically modified tomato CGN-89564-2 was among the first commercially available genetically engineered crop items to be granted a license for human consumption. Also dependent on DNA molecular marker technologies are the identification, evaluation, mining, and innovation of plant germplasm resources. Thus, it is expected that increasing RDT being used in food and agriculture will drive the original study segment's growth. Research on genetically modified organisms (GMOs), such as that on microorganisms that are regarded as bio degraders and generators of clean fuel, helps a wide range of additional sectors. Numerous human and plant illnesses are treated with genetically modified vaccinations. Recombinant DNA technology has opened up a variety of potential opportunities and prospects for creating a variety of therapeutic items with immediate effects in medical genetics and biomedicine. This is achieved by altering microbes, animals, and plants to produce medically valuable compounds.

North America dominated the market. The largest portion of the North American continent can be ascribed to the country's high concentration of biopharmaceutical manufacturing companies. Development aid has also been aided by the existence of powerful regulatory bodies that can keep an eye on the numerous ethical and scientific issues raised by the use of technology.

Feedback From Our Clients

"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "

- Mr. Ali Zali, Commercial Director, ICIIC Iran.

Recombinant DNA Technology Market News

Recombinant DNA Technology Market Report Snapshots

Want to customize this report?

FAQs

What is the market size of Recombinant DNA Technology Market?

Who are the key vendors in the Recombinant DNA Technology Market?

What is the key driver of Recombinant DNA Technology Market?

What is the key market trend for Recombinant DNA Technology Market?

Which region accounted for the largest share in Recombinant DNA Technology Market?

Request Free Customization

Related Reports

Feedback From Our Clients

$5,300